Champions Oncology, Inc. announced its financial results for the third quarter of fiscal year 2025, ended January 31, 2025, on March 11, 2025. The company reported record total revenue of $17.0 million, representing a 42% increase year-over-year. Gross profit reached $10.4 million, resulting in a gross margin of 61%.
The company achieved a record net income of approximately $4.5 million for the quarter, a substantial improvement from a loss in the prior year, and Adjusted EBITDA of $5.2 million. A significant highlight was the signing of its first data licensing deal, valued at up to $8.0 million, which marks a pivotal step in monetizing its proprietary data platform.
For the first nine months of fiscal 2025, total revenue increased 23% to $44.6 million, with a net income of $6.5 million and Adjusted EBITDA of $8.3 million. CEO Ronnie Morris described the quarter as 'transformational,' emphasizing the importance of the data licensing agreement and the hiring of Matt Newman as Executive Vice President and General Manager to lead the data licensing platform's expansion.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.